SOCIETY OF HEMATOLOGIC ONCOLOGY
SOHO 2024September 4-7, 2024
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| ABCL-006 | Azacytidine plus rituximabgemcitabineoxaliplatin as salvage treatment in patients with relapsed/refractory diffuse large B-cell lymphoma | Zong Dongfeng |  Received |
 |
|||
| CLL-027 | Tolerability and Outcomes of Oral Targeted Inhibitors for Chronic Lymphocytic Leukemia in Patients with Severe Renal Dysfunction | Clare Anderson | Received |
|
|||
| MM-036 | Impact of Multiple Myeloma in Remission on Hospitalization Outcomes Among Patients With Cerebral Infarction: Insights From the 2021 National Inpatient Sample Database | Kalaivani Babu | Received |
|
|||
| MM-037 | Demographic Characteristics of Hospitalized Patients With History of Multiple Myeloma in Remission: Insights From National Inpatient Sample 2021 | Kalaivani Babu | Received |
|
|||
| MM-038 | Beyond the Remission: How Does Beating Cancer Affect Your Heart Attack Outcomes? Impact of Multiple Myeloma in Remission on Hospitalization Outcomes in Patients with Acute Myocardial Infarction: Insights From a Retrospective Analysis of the 2021 National | Kalaivani Babu | Received |
|
|||
| MM-041 | Outcomes of Autologous Stem Cell Transplantation During Hospitalization for Multiple Myeloma With ESRD | Ani Gvajaia | Received |
|
|||
| CLL-42 | Identification and Diagnosis of Possible Mutations in Human p53 Lymphocytes | Aurelian Udristioiu | Received |
|
|||
| MCL-047 | Incidence, Predictors, and Outcomes of Atrial Fibrillation During Hospitalization for Mantle Cell Lymphoma | Michael Imeh | Received |
|
|||
| CLL-048 | Frequency of Practice-Changing Findings Identified by Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies | Katherine I. Zhou | Received |
|
|||
| MPN-051 | The Impact of New or Worsening Anemia on Clinical Outcomes in 2233 Patients With Myelofibrosis Treated With Ruxolitinib: Results From the Expanded-Access JUMP Study | Zoe Sand | Received |
|
|||
| MPN-052 | Ruxolitinib Treatment in Patients With Polycythemia Vera Reduces JAK2 Allele Burden and Improves Hematocrit Control and Symptom Burden | Zoe Sand | Received |
|
|||
| AML-054 | Efficacy Profile of Daily Injection Filgrastim in Chemotherapy-Induced (CT) Febrile Neutropenia (FN) in Patients With Acute Leukemia (AL): Ukrainian Retrospective Study in a Real-Life Cohort | Tetiana Lymanets | Received |
|
|||
| CML-056 | Case Report: Chylothorax in Patient With Chronic Myeloid Leukemia Secondary to Dasatinib Use | Irma Paniagua | Received |
|
|||
| CLL-057 | Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib Venetoclax for Chronic Lymphocytic Leukemia/SmallLymphocytic Lymphoma: Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study | Colleen McGowan | Received |
|
|||
| MCL-058 | Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma and TP53 Mutations in the SYMPATICO Study | Colleen McGowan | Received |
|
|||
| MDS-59 | Real-World Impact of Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) on the Healthcare Resource Utilization (HRU) of Patients With Myelodysplastic Syndromes (MDS) in the United States (US) | Eleni Tsepa | Received |
|
|||
| CLL-076 | Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Colleen McGowan | Received |
|
|||
| ABCL-081 | Epcoritamab as Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL) | Ning Dong | Received |
|
|||
| MPN-85 | Association Between Hemoglobin Improvement and Patient-Reported Outcomes in Patients With Myelofibrosis and Anemia: Post Hoc Pooled Analysis of Momelotinib Phase 3 Trials | Martha Shoup | Received |
|
|||
| MPN-086 | Time-Dependent Transfusion Status as an Independent Predictor of Overall Survival: A Post Hoc Analysis of 3 Phase 3 Trials | Martha Shoup | Received |
|
|||
| MPN-087 | Progression to Myelofibrosis (MF) in Patients With Essential Thrombocythemia (ET): An Analysis From the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | Haley Maire | Received |
|
|||
| MPN-88 | Transfusion Intensity Over Time in Patients From the Phase 3 SIMPLIFY-1 and MOMENTUM Trials of Momelotinib | Martha Shoup | Received |
|
|||
| MPN-089 | Demographic and Clinical Characteristics of Patients With Lymphoid and Hematopoietic Neoplasms Receiving Palliative Care: Insights From the National Inpatient Sample 2021 | Kalaivani Babu | Received |
|
|||
| MPN-092 | Association Between Major Depressive Disorder and Hospitalization Outcomes in Patients With Lymphoid and Hematopoietic Malignancies: A Population-Based Study | Kalaivani Babu | Received |
|
|||
| MPN-099 | Characteristics of Patients With Myelofibrosis and Essential Thrombocythemia Who Harbor a Calreticulin (CALR) Gene Mutation: Subanalysis of the MOST Study | Haley Maire | Received |
|
|||
| MPN-100 | High Rate of Disease Progression in Patients With Low-Risk Myelofibrosis (MF) Enrolled in the Prospective Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | Haley Maire | Received |
|
|||
| MPN-109 | Treatment Patterns and Blood Count Control in 10,112 Patients With Polycythemia Vera (PV) Managed at Community Practices in the United States (US) | Timothy Withers | Received |
|
|||
| MPN-112 | Bromodomain and Extra-terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis and Other Advanced Myeloid Neoplasms: A Phase 1 Study | Zoe Sand | Received |
|
|||
| AML-113 | Magrolimab Efficacy and Struggle for Approval in Acute Myeloid Leukemia: A Systematic Review | Ahmad Basharat | Received |
|
|||
| MCL-118 | Impact of early relapse (POD 24) & p53 alterations on treatment outcomes in patients with Mantle Cell Lymphoma: Multicentre, retrospective cohort study in Ireland. | EZZAT ELHASSADI | Received |
|
|||
| MPN-120 | A Real-World Evaluation of Risk Factors for Disease Progression in Patients With Polycythemia Vera (PV): An Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices (REVEAL) | Haley Maire | Received |
|
|||
| ABCL-122 | A Rare Case of Large B-cell Lymphoma Presenting as a Large Pericardial Effusion With Tamponade Physiology | Logan Deyo | Received |
|
|||
| ALL-126 | Cytogenetic Features and Prognosis of iAMP21 Acute Lymphoblastic Leukemia | Jiantuo Liu | Received |
|
|||
| MPN-135 | Safety and Efficacy of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor-Naïve Patients With Myelofibrosis: Latest Data From the Phase 3 MANIFEST-2 Study | Hannah Greetham | Received |
|
|||
| MPN-136 | Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery | Hannah Greetham | Received |
|
|||
| ALL-141 | Comparable Outcomes of Relapsed Acute Lymphoblastic Leukemia in Adolescents and Young Adults (AYA) Treated With Pediatric-Inspired Chemotherapy (R3 Protocol) Versus Adult-Based Salvage (FA) Protocol | Chokri Ben Lamine | Received |
|
|||
| CLL-144 | Real-World Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia Receiving First-Line Treatment with Venetoclax Obinutuzumab versus Brutons Tyrosine Kinase Inhibitors | Sophia S. Li | Received |
|
|||
| IBCL-147 | AC676, an Orally Bioavailable BTK Chimeric Degrader in Patients With B-cell Malignancies | Su Young Kim | Received |
|
|||
| ABCL-148 | Evaluating the Efficacy and Accuracy of ChatGPT in Providing Chemotherapy Education to Lymphoma Patients | Ahmad Basharat | Received |
|
|||
| TCL-149 | Breast Implant-Associated Anaplastic Large Cell Lymphoma Is an Increasingly Recognized Entity: Case Report | Fabiola Fuentes-Alfaro | Received |
|
|||
| MPN-153 | A Phase 1b Trial of DISC-0974, an Anti-hemojuvelin Antibody, in Participants With Myelofibrosis and Anemia | Chelsea Norregaard | Received |
|
|||
| MDS-156 | Efficacy of Imetelstat on Red Blood Cell (RBC)-Transfusion Independence (TI) in the Absence of Platelet Transfusions or Myeloid Growth Factors (MGF) in IMerge | Jessica Conte | Received |
|
|||
| MDS-157 | Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Jessica Conte | Received |
|
|||
| MDS-166 | Clinical Benefit of Luspatercept Treatment in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) in the COMMANDS Trial | Michael Rowlands | Received |
|
|||
| MDS-167 | Multilineage and Safety Results From the COMMANDS Trial in Transfusion-Dependent (TD), Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) | Michael Rowlands | Received |
|
|||
| CLL-171 | Medicare Part D Out-of-Pocket (OOP) Costs for Venetoclax vs. BTKis in Frontline CLL: Modeling the Benefits of Fixed-Duration Treatment and Changes Under the Inflation Reduction Act (IRA) | Beth Stapleton | Received |
|
|||
| AML-177 | Treatment Adherence and Persistence of FLT3 Inhibitors as Post-Allogenic Hematopoietic Cell Transplant Maintenance Therapy in Patients With Acute Myeloid Leukemia in the United States: A Cohort Study Using Administrative Claims Data | Samantha Sewell | Received |
|
|||
| MPN-179 | Targeting Endothelial-to-Mesenchymal Transition in a 3D iPSC-Based Model of JAK2V617F Myeloproliferative Neoplasms | Madeline J. Caduc | Received |
|
|||
| CML-180 | Role of Gut Microbiota in Defining the Clinical Outcomes of Patients With Chronic Myeloid Leukemia | Selene Grano | Received |
|
|||
| ABCL-183 | Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study | Samuel Bunting | Received |
|
|||
| CLL-184 | Characteristics Associated With Response to Lisocabtagene Maraleucel (liso-cel) in Patients With R/R CLL/SLL: Exploratory Analyses From the Phase 1/2 TRANSCEND CLL 004 Study | Carly Mercede | Received |
|
|||
| ABCL-185 | Mosunetuzumab wWth Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL) | Samuel Bunting | Received |
|
|||
| CLL-186 | Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia | Kelly Montenegro | Received |
|
|||
| CLL-189 | Real-world outcomes of lisocabtagene maraleucel in patients with Richter transformation from the Center for International Blood and Marrow Transplant Research (CIBMTR) | Alex Verdeur | Received |
|
|||
| ALL-191 | Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL) | Aileen Echeverry | Received |
|
|||
| ABCL-193 | Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study | Carly Mercede | Received |
|
|||
| CML-196 | Asciminib After One Prior Tyrosine Kinase Inhibitor (TKI) in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Real-World Chart Review Study in the United States (US) | Carmine Rossi | Received |
|
|||
| AML-197 | QuANTUM-First Trial: FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication (FLT3-ITD)Specific Measurable Residual Disease (MRD) Clearance Assessed Through Induction and Consolidation Is Associated with Improved Overall Survival in Newly Diagnosed FLT3-ITD AML Patients | Heather Duffy | Received |
|
|||
| CT-198 | Pooled Fecal Allogeneic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from the Early Access Program in Europe | Emilie Plantamura | Received |
|
|||
| CT-200 | A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating The Efficacy And Safety Of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy In Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: the PHOEBUS trial | Emilie Plantamura | Received |
|
|||
| AML-202 | QuANTUM-First: Effi cacy by Age in Newly Diagnosed Patients With FMS-Like Tyrosine Kinase 3-Internal Tandem DuplicationPositive Acute Myeloid Leukemia | Heather Duffy | Received |
|
|||
| MPN-203 | Anemia Burden in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): Data From the Veterans Affairs Corporate Data Warehouse (VACDW) | Peyton Little | Received |
|
|||
| ABCL-206 | Real-World Use of Tafasitamab for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the United States by Age Group (70 Years and =70 Years) | Catrina Tice | Received |
|
|||
| ABCL-207 | Real-World Use of Tafasitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the United States by Primary Refractory Status | Catrina Tice | Received |
|
|||
| CT-212 | National Trends in the Utilization of Chimeric Antigen Receptor T-Cell Therapy: The Real-World Story Since Its Approval | Divya Solipuram | Received |
|
|||
| AML-214 | The Role of Daratumumab in Treating Pure Red Cell Aplasia After Allogeneic Transplant in Patients With ABO Incompatibility: A Systematic Review | Ahmad Basharat | Received |
|
|||
| CT-219 | Clinical Evaluation of Fast-in-Time (FIT) Anti-CD19 CAR Ta Non-Viral, 2-Day Rapid Manufacture CAR T-Cell Therapy for B-Cell Malignancies | Hosein Kouros-Mehr | Received |
|
|||
| MPN-220 | Myelofibrosis Treatment Beyond Ruxolitinib: A Single-center Experience With Momelotinib and Pacritinib | Georgio Medawar | Received |
|
|||
| CLL-235 | Metabolic Reprogramming of Bone Marrow Stromal Cells in Chronic Lymphocytic Leukemia | Lotfi Chemali | Received |
|
|||
| MDS-238 | Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network | Peyton Little | Received |
|
|||
| CT-244 | Updated Clinical Progress of IL-10 expressing CD19 CAR-T Cells for Treatment of Relapsed or Refractory B-Cell Hematological Malignancies at Tiny Doses | Jingjing Ren | Received |
|
|||
| CLL-269 | Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From BTK-Naïve Cohort in the Phase 1/2 BRUIN Study | William Wierda | Received |
|
|||
| ABCL-272 | Epcoritamab R-DHAX/C Induces Deep, Durable Responses in Transplant-Eligible Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Including High-Risk Disease | Aileen Echeverry | Received |
|
|||
| MPN-274 | Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up | Jessica Litvan | Received |
|
|||
| ABCL-275 | Epcoritamab GemOx Induces Deep, Durable Responses in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Results From EPCORE NHL-2 | Aileen Echeverry | Received |
|
|||
| MDS-276 | Management of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoiesis-Stimulating Agent (ESA) Treatment | Eleni Tsepa | Received |
|
|||
| IBCL-278 | Epcoritamab With Rituximab Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7 | Aileen Echeverry | Received |
|
|||
| CLL-280 | Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 Trial | Aileen Echeverry | Received |
|
|||
| MPN-288 | Genomic and Molecular Analysis of Myelofibrosis Patients who received Momelotinib and Pacritinib at Moffitt Cancer Center | Jeremy DiGennaro | Received |
|
|||
| MM-295 | Timing And Outcomes of Second-Line Therapy in the Era of Daratumumab-Based Frontline Therapy in Amyloidosis | Abdul-Hamid Bazarbachi | Received |
|
|||
| CT-296 | Unveiling the Future: Insights From the Current Landscape in Solid Tumor CAR T Clinical Trials | Fathima Shehnaz Ayoobkhan | Received |
|
|||
| CT-299 | Comparison of Healthcare Utilization in Patients with Multiple Myeloma (MM) and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation (AHSCT) | Kim Abbegail Aldecoa | Received |
|
|||
| MPN-302 | Thorough QT Analysis of a Single Dose of Pacritinib: Results of the PAC107 Study | Blair Hesp | Received |
|
|||
| MM-318 | Perspectives of Single-Center Community Hematologists/Oncologists on Minimal Residual Disease Testing Among Patients With Multiple Myeloma | Chloe Henry | Received |
|
|||
| TCL-320 | Single Institution Experience of Pembrolizumab for Patients with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome | Omar Elghawy | Received |
|
|||
| ABCL-327 | Anatomical Pattern of CNS Relapse in Aggressive B-cell Lymphomas | Izel Okcu | Received |
|
|||
| CT-333 | Retrospective Single-Center Study of Extracorporeal Photopheresis as Second-Line Treatment for Chronic Graft-Versus-Host Disease | Yitzhar Goretsky | Received |
|
|||
| IBCL-335 | Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After =2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study | Samuel Bunting | Received |
|
|||
| MCL-339 | GLOBRYTE: A Phase III, Open-label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma | Samuel Bunting | Received |
|
|||
| ABCL-340 | Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume | Samuel Bunting | Received |
|
|||
| MCL-341 | Glofitamab Monotherapy In Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Updated Analysis From A Phase 1/2 Study | Samuel Bunting | Received |
|
|||
| CLL-342 | Comparison of Time to Next Treatment Between Patients With Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib Overall and in a Subgroup With High-Risk Characteristics | Abbey Poznanski | Received |
|
|||
| AML-347 | SELECT-AML-1: Phase 2 Randomized Trial of Tamibarotene in Combination With Venetoclax and Azacitidine in Adult Patients With Previously Untreated AML With RARA Overexpression, Who Are Ineligible for Standard Induction Therapy | Kristen Baker | Received |
|
|||
| ABCL-351 | LOTIS-5, an Ongoing, Phase 3, Randomized Study of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL | Matthew Noel | Received |
|
|||
| MDS-352 | Myelodysplastic syndromes with concomitant SF3B1 mutation and deletion of the long arm of chromosome 5 | Zaker Schwabkey | Received |
|
|||
| ABCL-353 | Phase 1b Open-Label Study of Loncastuximab Tesirine in Combination With Other Anticancer Agents in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Matthew Noel | Received |
|
|||
| MM-357 | Systematic Literature Review and Meta-Analysis of Clinical Trials of Fourth Line or Higher Treatment for Relapsed/Refractory Multiple Myeloma Patients | Eve Limbrick-Oldfield | Received |
|
|||
| MM-359 | Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens (SRs) in Triple-ClassExposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Sub-Analysis of Black Patients | Michael Rowlands | Received |
|
|||
| AML-360 | Mutational Landscape and Survival Outcomes of Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Harboring Cohesin Complex Mutations | Maria Khouri | Received |
|
|||
| CT-362 | Physician Density, Social Vulnerability, and Access to Allogeneic Hematopoietic Cell Transplant in Texas | Samantha E. Watters | Received |
|
|||
| MM-364 | Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-Up in all Patients | Rebecca Chan | Received |
|
|||
| ABCL-366 | Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma | Matthew Noel | Received |
|
|||
| ABCL-367 | Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL | Matthew Noel | Received |
|
|||
| ABCL-368 | Real-world Treatment Patterns and Outcomes of Patients with Large B-cell Lymphoma (LBCL) Who Received Loncastuximab Tesirine Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy | Matthew Noel | Received |
|
|||
| ABCL-370 | Real-World Clinical Effectiveness of Loncastuximab Tesirine Monotherapy for the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma Following Chimeric Antigen T-Cell Therapy in the US | Matthew Noel | Received |
|
|||
| MPN-384 | A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients With Myeloid/Lymphoid Neoplasms With Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Rearrangement | Catrina Tice | Received |
|
|||
| AML-385 | A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) | Heather Duffy | Received |
|
|||
| MPN-386 | Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With Pacritinib in the United States | Michael Marrone | Received |
|
|||
| AML-390 | Higher Relapse Rate and Resource Utilization With Ara-C Consolidation Chemotherapy Alone Compared With Hematopoietic Cell Transplantation in First Remission in a Cohort of Younger Adults With Acute Myeloid Leukemia With t(8;21) (q22;q22.1) | Ahmed Alahmadi | Received |
|
|||
| TCL-391 | Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial | Heather Duffy | Received |
|
|||
| TCL-394 | Valemetostat for Patients With Relapsed/Refractory Peripheral T-Cell Lymphomas: The Phase 2 VALENTINE-PTCL01 Trial | Heather Duffy | Received |
|
|||
| CML-396 | Safety, Tolerability, Pharmacokinetics, and the Effect of Food on TERN-701, an Oral Allosteric BCR-ABL Tyrosine Kinase Inhibitor, in Healthy Participants | Swapna Shenvi | Received |
|
|||
| MDS-397 | Efficacy and Safety Is Maintained in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for Up to 3 Years | Carl Friddle | Received |
|
|||
| CML-399 | CARDINAL: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Optimization Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Chronic Myeloid Leukemia | Megan McNamee | Received |
|
|||
| CML-400 | Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia (Ph ALL) | Paul Fletcher | Received |
|
|||
| CML-401 | Insights into Neulasta-Associated Splenic Infarction: Unveiling a Rare Complication in Chemotherapy for Chronic Myelomonocytic Leukemia | Supriya Peshin | Received |
|
|||
| CML-404 | Management of Chronic Myeloid Leukemia (CML) in Pregnant Women: A Comprehensive Literature Review | Tala Najdi | Received |
|
|||
| ABCL-406 | Real-World Sequential Use of CD19-Directed Therapies for Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab Preceding Chimeric Antigen Receptor T-Cell (CAR-T) Therapy | Catrina Tice | Received |
|
|||
| CML-409 | BCR-ABL Tyrosine Kinase Inhibitors: Renal Safety Considerations in Africa | Bereket Abraha Molla | Received |
|
|||
| ALL-410 | In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph ALL | Sara Cecere | Received |
|
|||
| ABCL-411 | Matching-Adjusted Indirect Comparison of Axicabtagene Ciloleucel vs Odronextamab for the Treatment of Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) After 2 Prior Lines of Systemic Treatment | Frederick L. Locke | Received |
|
|||
| CLL-414 | Phase 3 BELLWAVE-011 Study: Nemtabrutinib Versus Ibrutinib or Acalabrutinib in Previously Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Katherine Metzger | Received |
|
|||
| CLL-415 | Phase 3 BELLWAVE-010: Nemtabrutinib Plus Venetoclax Versus Venetoclax Plus Rituximab (VR) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Katherine Metzger | Received |
|
|||
| ABCL-417 | First Data From Subcutaneous Epcoritamab Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) for First-Line Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE NHL-5 | Daniel Alan Kerr | Received |
|
|||
| CML-425 | Dose-Optimization Study of 3 Starting Doses of Ponatinib: Long-Term Results From the OPTIC Trial | Sara Cecere | Received |
|
|||
| MM-429 | Prognostic Role of Serum Procalcitonin Levels in Hospitalized Patients With Malignant Pleural Effusion | Chioma Nwachukwu | Received |
|
|||
| CLL-431 | 4-Year Results With Ponatinib by Mutation Status in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML): OPTIC Study | Sara Cecere | Received |
|
|||
| ALL-438 | Minimal Residual DiseaseNegative Complete Remission As A Prognostic Indicator of Long-Term Survival in Adult Patients With Philadelphia ChromosomePositive Acute Lymphoblastic Leukemia | Sara Cecere | Received |
|
|||
| CT-439 | Clinical Experience of Tabelecleucel in EpsteinBarr Virus-Positive Posttransplant Lymphoproliferative Disease (EBV PTLD) Involving the Central Nervous System | David Schonberg | Received |
|
|||
| ALL-442 | Patient-reported Outcomes in Adults With Newly Diagnosed Ph Acute Lymphoblastic Leukemia Treated With Ponatinib or Imatinib in Combination With Reduced-Intensity Chemotherapy: Results From the Phase III PhALLCON Study | Sara Cecere | Received |
|
|||
| AML-443 | Real-World Outcomes of Acute Myeloid Leukemia Patients Undergoing Treatment With Tyrosine Kinase Inhibitor (TKI) Therapy Targeting FLT3, IDH1, or IDH2 | Manuel Espinoza Gutarra | Received |
|
|||
| HL-446 | From Hodgkin Lymphoma to Mycosis Fungiodes: A Quick Cascade | Shea-Lee Godin | Received |
|
|||
| HL-447 | Lymphoma Diagnosis Delay: Biopsy Strategy Insights | Shea-Lee Godin | Received |
|
|||
| MPN-451 | Influence of Heart Failure Upon Incidence Rates of Pneumonia, Acute Respiratory Failure, Sepsis and Septic Shock in Patients With Polycythemia Vera | Himil Mahadevia | Received |
|
|||
| MPN-452 | Allogeneic Stem Cell Transplant in Myelofibrosis Patients: A Real-World Analysis | Serena Tharakan | Received |
|
|||
| MM-453 | Effect of Heart Failure on Incidence Rates of Pneumonia, Sepsis and Septic Shock in Patients with Multiple Myeloma | Himil Mahadevia | Received |
|
|||
| IBCL-461 | A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States | Paul Cockrum | Received |
|
|||
| ALL-462 | Breaking Barriers: Pegaspargase Therapy in Adolescent and Young Adult Population Ages 14-55 Years Diagnosed With Acute Lymphoblastic Leukemia Evidence From a Single-Center Study | Samar Alshammasi | Received |
|
|||
| CLL-465 | Second Primary Malignancies (SPMs) in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With the Combination of a Targeted Agent With an Antibody in 4 Phase 2 Trials of the German CLL Study Group (GCLLSG) | Daniel Zaldumbide | Received |
|
|||
| MPN-470 | Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia | Blair Hesp | Received |
|
|||
| CLL-471 | Real-World Comparative Outcomes of First-Line (1L) Venetoclax Obinutuzumab (VenO) Versus Covalent Brutons Tyrosine Kinase Inhibitors (BTKis) Anti-CD20 Therapy Among Patients With Chronic Lymphocytic Leukemia (CLL) in the United States (US) | Sophia S. Li | Received |
|
|||
| CLL-479 | 6-Year Time to Next Treatment (TTNT) Extrapolation Curve for GLOW Study: First-Line Ibrutinib Plus Venetoclax (IV) Offers Long Treatment-Free Period for Older Adult/Unfit Patients With Chronic Lymphocytic Leukemia (CLL) | Abbey Poznanski | Received |
|
|||
| CLL-481 | Ibrutinib Efficacy Across Subgroups of Patients With High-Risk Chronic Lymphocytic Leukemia: A Systematic Literature Review | Abbey Poznanski | Received |
|
|||
| IBCL-483 | First Reported Use of Polatuzumab-RCHP in Follicular Lymphoma, With Excellent Response | Aatif Khurshid | Received |
|
|||
| CLL-487 | First-Line Fixed-Duration Ibrutinib Plus Venetoclax (IbrVen) vs Chlorambucil Plus Obinutuzumab (ClbO): 55-Month Follow-Up From the GLOW Study | Abbey Poznanski | Received |
|
|||
| MM-488 | Iberdomide, Bortezomib, and Dexamethasone (IberVd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial | Jennifer Mark | Received |
|
|||
| AML-490 | Deciphering Endothelial and Coagulation Disturbances in Patients With Acute Myeloid Leukemia at High Risk of Early Complications | Sofiane Fodil | Received |
|
|||
| MM-493 | Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) With Lenalidomide (R) Maintenance Versus R Maintenance Alone in Adult Patients With Newly Diagnosed Multiple Myeloma (NDMM) Who Have Suboptimal Response to Autologous Stem Cell Transplantation (ASCT) | Michael Rowlands | Received |
|
|||
| CLL-495 | Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies | Beth Stapleton | Received |
|
|||
| MPN-497 | Impact of Pacritinib on Symptoms in Thrombocytopenic Myelofibrosis Patients Who Require Red Blood Cell Transfusion | Blair Hesp | Received |
|
|||
| AML-498 | Pegcrisantaspase (PegC) Induces an Increase in Plasma Threonine in Patients With Acute Myeloid Leukemia (AML) | Yuchen Liu | Received |
|
|||
| MPN-499 | A Retrospective Analysis of Pacritinib Treatment Outcomes in Myelofibrosis Patients With and Without Monocytosis | Blair Hesp | Received |
|
|||
| MM-500 | Daratumumab (Dara) Versus Isatuximab (Isa): Perceptions of Anti-Cluster of Differentiation 38 (CD38) Monoclonal Antibody (mAb) Use in Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM) | Nicholas Moffett | Received |
|
|||
| MM-504 | Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome in Relapsed and Refractory Multiple Myeloma Using the FAERS Database | Fathima Shehnaz Ayoobkhan | Received |
|
|||
| MDS-508 | IDH1 Somatic Mutations Are More Commonly Observed Among Patients With Concomitant Myelodysplastic Syndromes and Connective Tissue Disease | Rami Komrokji | Received |
|
|||
| MDS-513 | Human Factors Validation Study for a Wearable, Single-Use Injector and a Survey of Real-World Device Use for Complement Inhibitor-Treated Patients With Paroxysmal Nocturnal Hemoglobinuria | Carl Friddle | Received |
|
|||
| IBCL-519 | Correlation Between Familial Waldenström Macroglobulinemia Clusters With Clinical Features, Complications, and Outcomes in 1000 patients: A Single-Center Retrospective Cohort Study | Andres Ramirez-Gamero | Received |
|
|||
| MM-520 | Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial | Jenny Mark | Received |
|
|||
| AML-521 | Treatment of Acute Myeloid Leukemia With Orca-T | Shahin Shafiani | Received |
|
|||
| ABCL-524 | Phase 1 Clinical Trial of LP-284 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas and Solid Tumors | Jianli Zhou | Received |
|
|||
| MPN-525 | Olutasidenib Demonstrates Promising Tolerability and Efficacy in IDH1-Mutated Accelerated/Blast Phase Myeloproliferative Neoplasms | Andrew Kuykendall | Received |
|
|||
| AML-526 | OLUTASIDENIB FOR MUTATED IDH1 ACUTE MYELOID LEUKEMIA: FINAL FIVE-YEAR RESULTS FROM THE PHASE 2 PIVOTAL COHORT | Jorge Cortes | Received |
|
|||
| MPN-527 | Selinexor and Ruxolitinib Impact on Symptom Burden in Patients With Myelofibrosis Is Potentially Driven by Inhibition of NF-?B and Activation of P53 Pathways | Jon Nilsen | Received |
|
|||
| MPN-529 | Real-World Clinical Outcomes in Patients With Myelofibrosis With and Without Baseline Anemia in the Mass General Brigham Integrated Delivery Network | Martha Shoup | Received |
|
|||
| AML-532 | RESPONSE TO OLUTASIDENIB IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) FOLLOWING VENETOCLAX FAILURE | Aaron Sheppard | Received |
|
|||
| MPN-539 | Retrospective Real-World Analysis of Baseline Characteristics, Treatment Patterns, and Survival in Patients With Myelofibrosis and Anemia Receiving Ruxolitinib | Martha Shoup | Received |
|
|||
| IBCL-541 | A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas | Sofía Huerga-Domínguez | Received |
|
|||
| MM-542 | Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | Martha Shoup | Received |
|
|||
| CT-551 | Long-Term Outcomes of Salvage Radiation Therapy in Relapsed/Refractory Large B-Cell Lymphoma Patients After CAR T-Cell Therapy Failure | Hazim Ababneh | Received |
|
|||
| AML-553 | Revival of the PLK1 inhibitor volasertib in relapsed/refractory acute myeloid leukemia | Markus Lacher | Received |
|
|||
| MM-557 | DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/refractory Multiple Myeloma (RRMM) | Martha Shoup | Received |
|
|||
| CML-558 | Genetic alterations in Chronic Myeloid Leukemia patients with Tyrosine Kinase Inhibitors resistance from Guatemala through Next-generation Sequencing | Anai Oliva | Received |
|
|||
| MM-559 | Update on Predictors of Progression in Smoldering Multiple Myeloma: A Systematic Review | Gustavo Garcia | Received |
|
|||
| AML-560 | Molecular Features Associated With CNS Disease in Acute Myeloid Leukemia | Jesus D. Gonzalez-Lugo | Received |
|
|||
| MM-563 | Immunotherapy Revealing Promising Outcomes in Smoldering Myeloma: A Systematic Review | Gustavo Garcia | Received |
|
|||
| CT-565 | Racial and Sex-Based Disparities and Trends in Common Psychiatric Conditions for Patients With Bone Marrow Transplant Hospitalization in the United States: An 8-Year National Cross-Sectional Study | Ahmad Basharat | Received |
|
|||
| CLL-573 | Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | TERESA DOMINGUEZ | Received |
|
|||
| ABCL-579 | Zilovertamab Vedotin (ZV) Alone or in Combination With Nemtabrutinib in Relapsed or Refractory (R/R) Aggressive and Indolent B-Cell Malignancies (waveLINE-006): An Open-Label, Phase 2 Basket Study | Katherine Metzger | Received |
|
|||
| IBCL-582 | A Challenging Diagnosis: Low-Grade B-Cell Non-Hodgkin Lymphoma Coexisting With Follicular T-Cell Lymphoma | Monge Jose | Received |
|
|||
| AML-591 | Barriers to Receiving Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Insights From a Large-Scale Multicenter Observational Study | Natalie Wuliji | Received |
|
|||
| MM-593 | Sociodemographic Trends in Multiple Myeloma-Related Mortality From 1999 to 2020 and Effect of the COVID-19 Pandemic | Parisa Aijaz | Received |
|
|||
| CLL-594 | Chronic Lymphocytic Leukemia With Richters Transformation Presented With Imminent Tumor Lysis Syndrome: Case Report | Modather Grain | Received |
|
|||
| MM-596 | Underlying Cause of Death in Patients With Multiple Myeloma: A 21-Year Mortality Analysis | Parisa Aijaz | Received |
|
|||
| ABCL-598 | Real-World Application of the CNS-IPI in the Management of Central Nervous System Prophylaxis for Patients With Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: A Single-Center Experience | Lucas Kaplan | Received |
|
|||
| MM-599 | The Outcome of Management of Multiple Myeloma in Sudanese Patients | Mutasim Idriss | Received |
|
|||
| CML-623 | XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib With Potential Implications for Its Clinical Use | olof harlin | Received |
|
|||
| CML-627 | Concomitant Acid-Reducing Agents With TKI Increases Time to Achieve Remission in Patients With CML: A Real-World Analysis of a US Claims Database | olof harlin | Received |
|
|||
| CML-628 | Impact on Healthcare Resource Utilization and Cost of Care of Concomitant Prescribing of Acid-Reducing Agents With Tyrosine Kinase Inhibitors: A US Payer Perspective | olof harlin | Received |
|
|||
| CT-630 | No Impact of Prophylactic Corticosteroid Use in Patients Receiving Axicabtagene Ciloleucel for Large B-Cell Lymphoma | Megan Melody | Received |
|
|||
| CML-633 | Population Pharmacokinetic (PopPK) Modeling for a Novel Nilotinib Formulation | Cassandra Matthews | Received |
|
|||
| CT-634 | Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation and Its Association With Donor Virus-Specific Cellular Immunity | Archana Sasi | Received |
|
|||
| CML-636 | Real-World Evaluation of Treatment Patterns Among Patients With Chronic-Phase Chronic Myeloid Leukemia (CML-CP) in a Large Community Oncology Setting | April Beeks | Received |
|
|||
| CLL-638 | Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Brutons Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell Malignancies | Lee Miller | Received |
|
|||
| MPN-641 | Quantitative CD34 Blast Cell Enumeration Using AI: Improving BMT Assessment in Myeloproliferative Neoplasms | Carlo Pescia | Received |
|
|||
| AML-649 | Insights Into the Epidemiological Landscape of Genetic Mutations in Acute Myeloid Leukemia Patients at American University of Beirut Medical Center | Hawraa Tarhini | Received |
|
|||
| MPN-652 | Long-Term Response to Selinexor in Patients With Myelofibrosis and Refractory or Intolerant to JAK Inhibitors: Follow-Up Results of a Single-Center, Phase II, Investigator-Initiated Trial (IIT) | Srinivas Tantravahi | Received |
|
|||
| CT-660 | DAIR to Be Different: Successful Use of DAIR Regimen, a Novel Treatment Combination for EBV-induced HLH | Adam Bouhadana | Received |
|
|||
| MDS-663 | Improved Risk Stratification of MDS Patients With IPSS-M: A Single-Institution Experience | habibe kurt | Received |
|
|||
| IBCL-666 | The Natural History of Asymptomatic (Smoldering) Waldenström Macroglobulinemia (WM): Factors Predicting Progression to Symptomatic WM and Transformation | David Kaldas | Received |
|
|||
| MM-667 | The Effect of Opportunity Index on Mortality From Hematologic Malignancies Across the United States From 2018 to 2022 | Natalie Akoto | Received |
|
|||
| ALL-676 | Blinatumomab With Tyrosine Kinase Inhibitor for Ph-Positive B-Acute Lymphoblastic Leukemia (B-ALL): Multicenter Retrospective Review | manar aleid | Received |
|
|||
| MDS-688 | Effects of In Vivo IL-8 Axis Blockade on Myeloid Derived Suppressor Cells (MDSC) in a Patient With High-Risk MDS and Excess Blasts | Alain Mina | Received |
|
|||
| MPN-690 | Clinical and Laboratory Characteristics of Patients With Primary Myelofibrosis in Azerbaijan According to Jak2V617F Mutational Status | Elmir Guluyev | Received |
|
|||
| AML-702 | Similar Characteristics of Older Adults with AML Receiving Intensive and Non-Intensive Treatments | Sara Tinsley Vance | Received |
|
|||
| AML-715 | Treatment of Acute Promyelocytic Leukemia in Patients With Renal Failure on Hemodialysis | Cristina Olivo-Freites | Received |
|
|||
| ABCL-716 | Delaying Chemotherapy in Diffuse Large B-Cell Lymphoma Has No Impact in Outcomes | Carlos Eduardo Quintero Hernandez | Received |
|
|||
| IBCL-717 | Management of an ALK-Positive Inflammatory Myofibroblastic Tumor With Concomitant Follicular Lymphoma: A Case Report | Shaniza Haniff | Received |
|
|||
| AML-727 | Clinical Characteristics and Outcomes of NUP98 Rearrangement in Adults with Acute Leukemia | Katherine Klein | Received |
|
|||
| TCL-732 | A Rare Case of Rapid Onset Fatal HLH Secondary to Large Granular T-cell Lymphocytic Leukemia | Maha Hameed | Received |
|
|||
| TCL-737 | A Global Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With EBV-Positive (EBV) Relapsed/Refractory Peripheral T Cell Lymphomas (NAVAL-1) | Kiran Vangipuram | Received |
|
|||
| ALL-748 | Venetoclax Added to Hyper-CVAD-Nelarabine and Pegylated Asparagine Improves Outcomes in Patients With T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Jayatsu Senapati | Received |
|
|||
| AML-750 | Global Burden and Trends in Acute Myeloid Leukemia in the European Union From 1990 to 2021: Insights from the Global Burden of Disease Study, 2021 | Dharmik Patel | Received |
|
|||
| CML-751 | Clonal Competition Between JAK2 and BCR-ABL in Myeloproliferative Neoplasm | Gabriel Salk | Received |
|
|||
| IBCL-753 | PROMising Developments: Trends of Patient-Reported Outcomes in Waldenström Macroglobulinemia Clinical Trials | Nitya Batra | Received |
|
|||
| MM-761 | Multiple Myeloma Mortality Trends Before Pandemic, Stratified by Year, Sex, and Race: 1999-2019 | Muhammad Faisal Aslam | Received |
|
|||
| HL-767 | Mortality Trends Related to Lymphoma in the USA Stratified by State, Year, Sex, and Race; 1999-2019 | Muhammad Faisal Aslam | Received |
|
|||
| MCL-771 | Unusual Presentation of Pleomorphic Mantle Cell Lymphoma and Comparative Study of Clinical Features With Previously Published Cases | Ifeoma Achebe | Received |
|
|||
| IBCL-802 | The Masked Intruder: Rasburicase Unveiling Methemoglobinemia in Tumor Lysis Syndrome | Supriya Peshin | Received |
|
|||
| MPN-10000 | Impact of Pacritinib on Symptoms in Thrombocytopenic Myelofibrosis Patients Who Require Red Blood Cell Transfusion | Daniel Zaldumbide | Received |
|
|||
SOHO 2024
September 4-7, 2024
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 04/09/2024 TO 07/09/2024
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
